About Jiangsu Hengrui Pharmaceuticals Company

The company was founded in 1970 and listed on the Shanghai Stock Exchange in 2000. It is an innovative international pharmaceutical enterprise focusing on R&D, production and promotion of high-quality drugs. It focuses on research and development of new drugs in the fields of anti-cancer, metabolic diseases, autoimmune diseases, respiratory diseases, neurological diseases, etc., and is one of the leading pharmaceutical companies with the most innovative ability in China. The company's main business involves R&D, production and sales of pharmaceuticals. Main products: imrecoxib, apatinib mesylate, tipefigestine, pyrrolitinib maleate, carelizumab, rimazolam toluene sulfonate, fluzoparil, haizepoparidine, darcilamide, aderbelimab, regagliptin phosphate, tegillidine fumarate, limpelizide, orteconazole. Corporate honors: “Environmental Exemplary Enterprise” and “Leading Green Development Enterprise” in Jiangsu Province, won the Lianyungang Economic and Technological Development Zone Enterprise “Environmental Protection Quality Award” in 2023, won the honorary title of “First Batch of Sterile Drug Quality Assurance Enterprises” issued by the China Pharmaceutical Quality Management Association, and the honorary title of “Jiangsu Pharmaceutical Industry Excellent Quality Management Enterprise” issued by the Jiangsu Pharmaceutical Quality Management Association; the company's “Young Eagle QC Group” and “Yuanzhi QC Group” were rated as excellent exchange groups for Jiangsu Pharmaceutical Industry Quality Management (QC).